What Is NAD+? Research Overview

NAD⁺ (β-nicotinamide adenine dinucleotide, oxidized form) is one of the most heavily studied molecules in biochemistry. Every cell uses it to move electrons through energy metabolism, and a growing set of enzymes break it down to send signals about DNA damage, nutrient status and stress. Few small molecules sit at so many crossroads.

Over the past two decades, interest has shifted from NAD⁺ as a textbook cofactor to NAD⁺ as a regulated pool whose size changes with tissue, age and metabolic state. This overview covers the molecule’s history and structure, its two roles as redox carrier and consumed substrate, the main lines of preclinical research, and the practical and interpretive limits of that research.

At a glance

• Class: Dinucleotide coenzyme; endogenous metabolite
• Origin: Identified as a heat-stable yeast fermentation factor (“cozymase”) by Arthur Harden and William Young in 1906
• Structure: Adenosine and nicotinamide riboside joined by a pyrophosphate bridge; C₂₁H₂₇N₇O₁₄P₂; MW 663.4 g/mol; CAS 53-84-9
• Main research areas: redox metabolism, sirtuin and PARP biology, CD38 and NAD⁺ consumption, NAD⁺ biosynthesis and salvage, tissue NAD⁺ levels in aging rodents
• Regulatory status: Endogenous metabolite; the material sold here is a research reagent, not an FDA-approved drug product

Structure and origin

Harden and Young noticed that boiled yeast extract contained a small, dialyzable factor needed for fermentation. Its chemical identity took decades to work out. Hans von Euler-Chelpin characterized the dinucleotide structure, and he and Harden shared the 1929 Nobel Prize in Chemistry for work on fermentation. In the 1930s Otto Warburg showed that the nicotinamide portion carries hydrogen in enzymatic reactions, which established its role in biological oxidation.

The molecule has two halves. An adenosine monophosphate is linked through a pyrophosphate bond to nicotinamide mononucleotide. The positively charged nicotinamide ring is the business end: it accepts a hydride ion (two electrons and a proton) to form NADH, and gives it back during oxidation. The phosphorylated relatives NADP⁺ and NADPH serve mainly in biosynthesis and antioxidant defense. Because of the pyrophosphate and charged ring, NAD⁺ is highly polar and crosses intact cell membranes poorly.

Mechanism: what the research shows

As a redox carrier, NAD⁺ is recycled rather than consumed. Dehydrogenases in glycolysis, the tricarboxylic acid cycle and fatty-acid oxidation reduce it to NADH, and complex I of the respiratory chain oxidizes NADH back to NAD⁺. The NAD⁺/NADH ratio is therefore a readout of cellular redox state (Verdin, 2015).

The second role is as a substrate that is used up. Sirtuins (SIRT1–7) remove acyl groups from proteins and release nicotinamide; poly(ADP-ribose) polymerases (PARPs) build ADP-ribose chains at sites of DNA damage; and CD38 and CD157 hydrolyze NAD⁺ or convert it to signaling metabolites. Because these enzymes compete for the same pool, heavy PARP activation or rising CD38 expression can lower NAD⁺ available to sirtuins. Cells replace the pool from tryptophan (de novo), nicotinic acid (Preiss-Handler pathway) and, mainly, nicotinamide salvage through the rate-limiting enzyme NAMPT (Covarrubias et al., 2021; Katsyuba et al., 2020).

Key areas of study

Sirtuins, PARPs and competition for the pool

Enzyme kinetics, knockout mice and pharmacological inhibitors have been used to show how NAD⁺ consumers interact. A review by Cantó and colleagues drew on this mouse and cell work to describe how mitochondrial and nuclear NAD⁺ pools influence sirtuin activity and oxidative metabolism (Cantó et al., 2015).

NAD⁺ decline in aging models

Several rodent studies reported lower NAD⁺ levels in tissues such as liver, muscle and adipose tissue with age. Proposed causes include increased consumption by CD38 and PARPs and reduced NAMPT-dependent salvage. Reviews of this work treat the NAD⁺ pool as one of several metabolic variables that change with age in model organisms (Covarrubias et al., 2021; Verdin, 2015).

Precursor and pathway studies

Much of the in vivo literature uses precursors rather than NAD⁺ itself, particularly nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), to raise tissue NAD⁺ in rodents. Rajman and colleagues reviewed these studies across metabolic, neurological and cardiovascular models and highlighted differences in study design, tissue response and measurement methods (Rajman et al., 2018).

Homeostasis and compartmentalization

NAD⁺ exists in separate cytosolic, nuclear and mitochondrial pools, and extracellular NAD⁺ is processed by cell-surface enzymes before uptake of its breakdown products. Mapping these compartments and their transporters is an active area of research (Katsyuba et al., 2020).

What the evidence does not show

Measuring NAD⁺ accurately is harder than it looks. Values depend on extraction method, speed of sample handling and whether total or compartment-specific pools are measured, so numbers differ widely between laboratories. Most whole-animal findings involve precursors, not NAD⁺ itself, and extracellular NAD⁺ is largely broken down before cells take up its components, which complicates interpretation of studies that add it directly. Age-related decline has not been found uniformly in every tissue or species. Rodent results do not establish effects in people.

Regulatory status

NAD⁺ is an endogenous metabolite. The NAD⁺ sold by Rogue Compounds is a research reagent, not an FDA-approved drug product, and it is not for human or veterinary use.

Handling and storage in the lab

Lyophilized NAD⁺ should be kept sealed and refrigerated at 2–8°C (36–46°F), protected from light. The dry powder takes up moisture readily, so keep the vial closed between uses.

Sourcing and documentation

Rogue Compounds offers NAD⁺ as a lyophilized powder, made in small batches in 500mg and 1000mg amounts. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch. The same batch COA is posted on the product page and in the COA Library.

View NAD+ (Lyophilized) on Rogue Compounds

References

1. Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. PMID 26785480
2. Covarrubias AJ, et al. NAD⁺ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. PMID 33353981
3. Katsyuba E, et al. NAD⁺ homeostasis in health and disease. Nat Metab. 2020;2(1):9-31. PMID 32694684
4. Cantó C, Menzies KJ, Auwerx J. NAD⁺ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22(1):31-53. PMID 26118927
5. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. PMID 29514064

Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.